Business Wire

Bluehole Publishes an Industry Comment on the World's First E&L Testing Laboratory in the Vaping Industry

29.3.2022 05:13:00 EEST | Business Wire | Press release

Share

China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on SMOORE‘s establishment of the world’s first E&L testing laboratory in the vaping industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005929/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SMOORE E&L Testing Lab (Photo: Business Wire)

Here below is the full article:

SMOORE, a global leader in offering vaping technology solutions, today announced the establishment of the world’s first extractable and leachable (E&L) testing laboratory in the vaping industry.

Built in the last half of 2021, this laboratory conducts qualitative and quantitative analytical testing and health risk assessment of E&L substances of electronic atomization components, including metals, plastics and other polymers.

As China’s first electronic atomization company to develop a PMTA (Premarket Tobacco Product Applications)-compliant assessment system, including physical tests, chemical tests, non-clinical testing and health risk assessment, SMOORE also set up this E&L testing laboratory based on PMTA safety requirements.

Moreover, SMOORE's E&L testing laboratory is in collaboration with SMITHERS, a world-leading provider of testing, consulting, information, and compliance services. For years, the two companies have worked closely on PMTA compliance.

Currently, most companies in the vaping industry rely on third-party laboratories for E&L testing while SMOORE has set up an in-house laboratory with comprehensive and advanced testing equipment. It follows the analytical methodology of the world’s leading E&L testing laboratories for medical devices.

As SMOORE’s flagship atomization tech brand, FEELM is able to make full use of SMOORE’s world-class testing and risk assessment system, including this E&L testing laboratory. Since 2021, FEELM has leveraged the laboratory for the safety assessment of its electronic atomization components, to guarantee the quality and reliability of FEELM's new products.

In October 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK has planned to integrate medicinally licensed e-cigarettes into the National Health Service (NHS). Other countries, including Australia, have also prescribed adult smokers e-cigarettes to reduce smoking rates. As global regulators started embracing e-cigarettes, they are setting higher safety requirements for e-cigarettes, and SMOORE takes the lead to improve the material reliability of e-cigarettes to medical grade.

E&L analytical testing is widely used in the field of pharmaceutical research and development. The E&L compounds of the packaging materials of pharmaceutical products must be tested before launch, to ensure the product safety compliance.

SMOORE's E&L testing laboratory can provide safety assessment for not only e-cigarettes but also electronic atomization products in other sectors. With one of its R&D focus on the application of atomization technology in healthcare and pharmaceutical fields, SMOORE could leverage this laboratory for the development of healthcare atomization innovations.

"The safety of electronic atomization products primarily depends on the chemical composition of e-liquid and the vapor generated by e-liquid atomization, as well as the E&L substances of other materials in contact with human bodies", said Dr. Long, Director of Analytical Testing and Safety Assessment of SMOORE Fundamental Research Center. "Our E&L testing laboratory specializes in the latter."

According to Dr. Long, SMOORE Fundamental Research Center plans to establish and complete a database of E&L substances in electronic atomization components, and will adopt the principle of Good Laboratory Practice (GLP) to ensure the quality and integrity of test data related to non-clinical safety studies. Meanwhile, SMOORE Fundamental Research Center is also looking for partnership with more Chinese medical device providers on E&L testing.

Since 2020, SMOORE has established its own safety standards, SMOORE 3.0, in accordance with the risk assessment guidance of U.S. EPA (Environmental Protection Agency). Above the safety requirements of the Tobacco Products Directive (TPD) of the EU and AFNOR of France, SMOORE 3.0 covers all of the PMTA tests, including both material safety and vapor safety.

To read the original article, please visit: https://www.bluehole.com.cn/news/detail/49078

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chen Bianji
(86)13530848319

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NetApp Data Platform Powers Data Operations for Super Bowl LX27.1.2026 15:00:00 EET | Press release

NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it is powering data operations for Super Bowl LX. As the Official Intelligent Data Infrastructure Partner of the San Francisco 49ers and the National Football League (NFL), NetApp provides the enterprise-grade data platform that powers the digital and physical experiences for football fans, whether watching the game from Levi’s® Stadium or from their couch on the other side of the world. “The world runs on data, even in an industry as physical as sports,” said Gabie Boko, Chief Marketing Officer at NetApp. “Optimizing data for innovation isn’t just about where the data lives, but also about how it moves. There is no place where that will be on display more clearly than Levi’s® Stadium during the Super Bowl. While the stadium is not a traditional data center, during a game, it transforms into an interactive data center because data is moving everywhere.” As football has evolved with technology, the

REVEAL GENOMICS Aligns Founder Leadership With Priorities to Support Long-term Growth, Scientific Excellence, and Global Partnerships27.1.2026 14:43:00 EET | Press release

REVEAL GENOMICS, a Barcelona-based biotechnology company that advances precision oncology through biomarker innovation, today announced a strengthened leadership framework with several senior appointments. These appointments underscore the company’s commitment to scientific excellence, technological rigor, and clinical impact, and they seek to support the continued development, validation, and global adoption of the company’s genomic assays. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127015446/en/ The company appoints Ana Vivancos, Ph.D., as Director of NGS and Genomic Technologies; Joel Parker, Ph.D., as Chief Scientific Officer; and Aleix Prat, M.D., Ph.D., as Chairman of the Board of Directors. The roles are assumed by co-founders of REVEAL GENOMICS and are a reflection of the company’s strong internal leadership, continuity of vision, and long-term commitment to its scientific and clinical mission. By aligning its

Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease27.1.2026 13:00:00 EET | Press release

Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that 75% of patients currently enrolled in its ongoing Phase 2b clinical study ACTIVATE (ClinicalTrials.gov identifier: NCT05819359) have completed the double-blind treatment period through week 78. This operational milestone represents a significant step toward the completion of the ACTIVATE study, which is evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). The date of the Last Patient, Last Visit (LPLV) is anticipated in April 2026, with topline results on track to be released in mid-2026. “We look forward to presenting data from our Phase 2b study. BIA 28-6156 is the leading asset in GBA-PD, and clinical outcomes are just around the corner,” said António Portela, CEO of Bial. “We are witnessing growing

Libraesva and Cyber Guru Announce Strategic Combination to Create a Leading European Human-Centric Cybersecurity Provider27.1.2026 12:00:00 EET | Press release

Cyber Guru and Libraesva today announced a strategic combination that brings together two highly complementary Italian cybersecurity companies to form a new European leader in human-centric cyber protection. The combined group will offer organisations an integrated approach to defending against email-based threats, social engineering, and human-targeted attacks, integrating advanced technology with behavioural resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127531600/en/ Cyber threats are evolving rapidly, with attackers focusing less on infrastructure and more on the weak link in security – human behaviour. Phishing, business email compromise, smishing, QR-code attacks, social engineering and many other forms of attacks targeting humans continue to be primary breach vectors and are rapidly growing in sophistication with support of widely available AI tools. By integrating Libraesva’s advanced, privacy-first em

Europe’s First Meteorological Infrared Sounder Reveals the Atmosphere in 3D27.1.2026 11:30:00 EET | Press release

The first images from Europe’s pioneering meteorological infrared sounder were unveiled today at the EU Space Conference in Brussels, marking a major advance in the ability to monitor how the atmosphere evolves before and during severe weather. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127490399/en/ Full Earth disc image from the MTG-S Infrared Sounder showing a surface-temperature-sensitive channel, captured between 12:45 and 15:30 UTC on 15 November 2025. The image distinguishes land and sea surface temperatures as well as cloud-top temperatures, highlighting cloud structures and weather systems. Hot desert regions appear in red, while cold cloud tops are shown in blue. © Image: Data acquired on 15 November 2025 and processed by industrial partners Thales and OHB under the supervision of EUMETSAT and ESA. Visual produced by EUMETSAT. The images were captured by the Infrared Sounder (IRS) flying aboard Meteosat Thir

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye